Beta Bionics, Inc. (BBNX)

Mixed fundamentals: a hyper-growth medical-device story (54% revenue growth, Mint patch pump FDA-cleared September 2026, ~$225M cash with runway into H1 2028) is offset by deep operating losses, negative cash flow and DCF values, an unresolved FDA Warning Letter, a new securities class action, and heavy insider selling with no buys. Watchlist-caliber rather than cleanly strong.

Dominant catalyst is the 2026-09-14 FDA clearance of the Mint tubeless patch pump (product, announced confidence, market-rewarded: all in-window coverage scored +0.4 to +0.5 and the stock rose), offset by a $172.5M dilutive offering closed 2026-09-17 and a lowered FY2026 revenue guide. Sentiment delta is a determinate improvement (baseline ≈ +0.01 → scoring ≈ +0.44); moderate red-flag cap applied (growth-context dilutive offering; conflicting catalyst signals).

Price 21.89 trades above SMA20 19.29, SMA50 17.61, SMA200 16.25, EMA9 19.93, EMA21 19.11 and Friday's VWAP 21.61 after a +32% five-session re-rating on the Mint FDA clearance and the closed $172.5M offering; MACD 0.80/0.56 with histogram +0.24 and expanding, ADX14 29.65 rising, RSI14 64.72 — trend and momentum are firmly bullish. Weak signal: short-term overbought (Williams %R -10.77) with volume cooling from the 09-16 climax. Nearer support limits (21.10/20.39), a market entry (overhead 22.66 within 1 ATR) and breakout stops above 22.16/22.66 all produce R/R < 1.0 against the structure stop anchored to the 09-15 base low (16.37 - 0.31 buffer = 16.06), so the actionable plan is a deeper GTC pullback limit at 19.15 in the EMA21/SMA20 confluence, giving R/R 1.01.